Advertisement

Topics

Latest "Galectin Therapeutics" News Stories

12:36 EDT 18th August 2017 | BioPortfolio

Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Galectin Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.

Showing "Galectin Therapeutics" News Articles 1–25 of 8,900+

Extremely Relevant

Galectin Therapeutics Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Updated: 04052017] Prices from USD $350

Galectin Therapeutics Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Galectin Therapeutics Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions un...


Galectin Therapeutics: 1 More Shot To Get It Right?

Relevant

Galectin Therapeutics: Serendipity In Psoriasis, Strength In NASH


Galectin Therapeutics to Present at the Singular Research Summer Conference

NORCROSS, Ga., July 07, 2017 (GLOBE NEWSWIRE) Read more...

Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update

NORCROSS, Ga., Aug. 14, 2017 (GLOBE NEWSWIRE) Read more...

Galectin Therapeutics Inc GALT Financial and Strategic SWOT Analysis Review [Updated: 15052017] Prices from USD $300

SummaryGalectin Therapeutics Inc Galectin Therapeutics, formerly ProPharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company's products comprise GRMD02 and GMCT01. Its GRMD02 is a drug candidate used for treating fibrotic liver disease. Its GMCT01 is a vaccine used to treat patients with advanced melanoma, a...

Galectin Therapeutics Inc GALT Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

SummaryGalectin Therapeutics Inc Galectin Therapeutics, formerly ProPharmaceuticals Inc is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company's products comprise GRMD02 and GMCT01. Its GRMD02 is a drug candidate used for treating fibrotic liver disease. Its GMCT01 is a vaccine used to treat patients with advanced melanoma, a d...

Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance

Activation of dectin-1-dependent signaling in macrophages through ligation by galectin 9 promotes an immunosuppressive, protumorigenic microenvironment in pancreatic adenocarcinoma (PDA). Blocking dectin 1 ligation restores anti-tumor immunity and delays tumor growth, thus offering a novel strategy for improving the effectiveness of immunotherapy in patients with PDA.

Galectin Therapeutics Inc GALT Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 25042017] Prices from USD $250

SummaryGalectin Therapeutics Inc Galectin Therapeutics, formerly ProPharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company's products comprise GRMD02 and GMCT01. Its GRMD02 is a drug candidate used for treating fibrotic liver disease. Its GMCT01 is a vaccine used to treat patients with advanced melanoma, a...

Galectin Therapeutics Inc GALT Medical Equipment Deals and Alliances Profile [Report Updated: 12072017] Prices from USD $250

SummaryGalectin Therapeutics Inc Galectin Therapeutics, formerly ProPharmaceuticals Inc is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company's products comprise GRMD02 and GMCT01. Its GRMD02 is a drug candidate used for treating fibrotic liver disease. Its GMCT01 is a vaccine used to treat patients with advanced melanoma, a d...

DSMB recommends continuation of Galectin's Phase IIb NASH trial

Autoimmune Disease Patent Granted To Galectin

  Life Sciences Jobs   ...

Patent For Reducing Inflammatory Response Granted To Galectin

  Life Sciences Jobs   ...

Galectin Announces Important Milestones Towards Completion Of NASH CX Trial

  Life Sciences Jobs   ...

Patent For Enhancing Immunotherapy In Cancer Treatment Granted To Galectin

  Life Sciences Jobs   ...

Galectin Reports 2017 First Quarter Financial Results And Provides Business Update

  Life Sciences Jobs   ...

Galectin Reports 2017 Second Quarter Financial Results And Provides Business Update

  Life Sciences Jobs   ...

Galectin Receives Notice Of Japanese Decision To Grant A Composition Of Matter Patent For GR-MD-02

  Life Sciences Jobs   ...

Clarification: Galectin Reports 2017 Second Quarter Financial Results And Provides Business Update

  Life Sciences Jobs   ...

Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells

Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 Pipeline Review, H1 2017 [Updated: 20062017] Prices from

Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 Pipeline Review, H1 2017SummaryGalectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protei...

Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1) - Pipeline Review, H2 2017

LONDON, July 31, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/5026449/SummaryGalectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) pipeline Target con...

Concurrent with BMS acquisition, IFM Therapeutics spins off IFM Therapeutics LLC

Innate immunity-focused IFM Therapeutics is spinning off its non-oncology assets into the new company IFM Therapeutics LLC. ...

Galectin Launches /i>, An Online Community And Publication On Liver Health And Liver Disease

  Life Sciences Jobs   ...

Galectin Therapeutics Submits Fast Track Application to FDA for GR-MD-02 in Treatment of Fatty Liver Disease with Advanced Fibrosis

NORCROSS, Ga., July 1, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it has submitted a Fast Track application to the FDA to help expedite its clinical development program of GR-MD-02 in the treatment of non-alcoholic steatohepatitis (NASH, or fatty liver disease...


Quick Search
Advertisement
 

News Quicklinks